±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 2006  |  »Ø¸´: 15
¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û6´Î£¬×÷Õßpceek001Ôö¼Ó½ð±Ò 3.5 ¸ö
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

pceek001

³¬¼¶°æÖ÷

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


[×ÊÔ´] Ò©ÀíѧÃû´ÊÖÐÓ¢ÎĶÔÕÕ±í

ҩѧÃû´Ê£¨ÖÐ-Ó¢£©

6-Á×ËáÆÏÌÑÌÇÍÑÇâø glucose-6-phosphate dehydrogenase
Janbon×ÛºÏÖ¢ Janbon's syndrome
PPBŨ¶È parts per billion concentration
pphmŨ¶È parts per hundred million concentration
PPHŨ¶È parts per hundred concentration
ppmŨ¶È parts per million concentration
°²È«·¶Î§ safety range
°²È«ÊÔÑé·¨ innocuity test method
°²È«ÏµÍ³ safety coefficient
°²Î¿¼Á placebo
òüºÏ¼Á chelating agent
°Ðϸ°û target cell
°×µ°°×΢ÇòÖÆ¼Á albumin microballoons
°Ù·ÖŨ¶È percentage concentration
°ëºÏ³É¿¹ÉúËØ semisynthetic antibiotics
°ë¿¹Ô­ haptene
°ëÊýÖÂËÀ¼ÁÁ¿ half lethal dose ; median lethal dose; LD50
°ëË¥ÆÚ half-life period; half life time
°üÒÂÆ¬ coated tablet
±¡Ä¤Ò film-coating
±¥ºÍÈÜÒº saturated solution
±´¿ËÀÕ¶û Becquerel
±»¶¯ÃâÒß passive immunity
±»¶¯×ªÔË passive transport
±À½â¶È disintegration
±À½â¼Á disintegrants
±ØÐè°±»ùËá essential aminoacid
±ØÐèÖ¬·¾Ëá essential fatty acid
±ä̬·´Ó¦ allergy; allergic reaction
±íÃæ»îÐÔ surface activity
±íÃæÕÅÁ¦ surface tension
±ûÖÖÉäÏß gamma rays
²¹Ìå complement
²¹Ìåϵͳ complement system
²»Á¼·´Ó¦ adverse reaction
²»ÍêÈ«¿¹Ô­ incomplete antigen
²ë¼Á liniments
³¤ÆÚ¶¾ÐÔʵÑé long term toxicity test
³¤Ð§ÖƼÁ prolonged action preparation
³¦¸ÎÑ­»· enterohepatic circulation
³¦ÈÜ¿ØÊÍÆ¬ enteric controlled release tablets
³¦ÈÜÒ enteric coating
´¦·½ prescription;recipe
´©Í¸´Ù½ø¼Á penetration enhancers
´ÅÐÔ¿ØÊÍÖÆ¼Á magnetic controlled release dosage form
´ÅÐÔÒ©ÎïÖÆ¼Á magnetic medicinal preparations
´ó·Ö×Ó macromolecule
µ¥¿Ë¡¿¹Ìå monoclonal antibody
µ¨¼îõ¥Ã¸ cholinesterase
µ±Á¿ equivalent weight
µ±Á¿¶¨ÂÉ equivalent law
µ±Á¿Å¨¶È normality
µ±Á¿ÈÜÒº normal solution
µÈÕÅÈÜÒº isotonic solution
µÍ¾ÛÌÇ oligosaccharides
µÍÃܶÈÖ¬µ°°× low density lipoprotein
µÎ¶¨ titration
µÎ¶¨ÇúÏß titration curve
µÎÍè¼Á pill
µÝÖÊ transmitter
µç½â electrolyzation
µç½âÖÊ electrolyte
ôú¼Á tincture
¶¨ÏòÒ©ÎïÖÆ¼Á directed pharmaceutical preparations
¶¾Àíѧ toxicology
¶¾ÐÔ·´Ó¦ toxic response; toxic reaction
¶ÌÆÚÖ°©ÊµÑé short term carcinogenic test
¶ÔÒòÖÎÁÆ etiological treatment
¶ÔÓ³Ìå antipode
¶ÔÖ¢ÖÎÁÆ symptomatic treatment
¶à¹¦ÄÜø multifunctional enzyme
¶à¼ÁÁ¿¸øÒ© multiple dose administration
¶àÌÇ polyose
¶àëÄ polypeptide
¶ù²è·Ó°· catecholamine
¶þÖØ¸ÐȾ superinfection
·¢½Í fermentation
·¨¶¨´¦·½ official formula
·¼×廯ºÏÎï aromatic compound
·ÅÉä¶¾Àíѧ radiotoxicology
·ÅÉäÒ©¼Áѧ radiopharmaceutics
·Ç±ØÐè°±»ùËá non-essential amino acid
·ÇÈ¥¼«»¯Ðͼ¡ËÉÒ© nondepolarizer
·Ö×Ó²¡ molecular disease
·Ö×ÓÈÜÒº molecular solution
·Ö×ÓÉúÎïѧ molecular biology
·Ö×ÓÒ©Àíѧ molecular pharmacology
¸¨»ù prosthetic group
¸¨ÁÏ excipients
¸¨Ã¸ coenzyme
¸±×÷Óà side effect
¸½¼Ó¼Á additive
¸ÉÔï¼Á desiccant;drying agent
¸ÎÊ×¹ýЧӦ first pass effect of hepar
¸ÐÊÜÆ÷ receptor
¸ßÃôÐÔ hyperreactivity
¸öÌå²îÒìÐÔ individual differences; individual variation
¸øÒ©·½°¸»ò¸øÒ©ËÙ¶È dosage regimen or dose rate
¸øÒ©¼ä¸ô dosing interval
¹¤ÒµÒ©¼Áѧ industrial pharmacy
¹²¼Û¼ü covalent bond
¹âÁ¿×Ó light quantum
¹ãÆ×¿¹ÉúËØ broad-spectrum antibiotic
¹ýÂË filtration
¹ýÃô¶¾ËØ anaphylatoxin
¹ýÃôÐÔÒ©Îï·´Ó¦ anaphylactic drug reaction
¹ýÑõ»¯Îï superoxide
º¬Á¿¾ùÔÈ¶È content uniformity
ºËÌǺËËá ribonucleic acid; RNA
ºËÜÕËá nucleotide
ºÏ²¢ÓÃÒ© drug combination
ºÏ³ÉÒ©Îï synthetic drugs
ºÏ¼Á mixture
ºÛÁ¿ÔªËØ trace element
»¯Ñ§·ÖÎö chemical analysis
»¯Ñ§ÎïÀíѧ chemical physics
»¯Ñ§Ïû¶¾·¨ chemical disinfection
»¯Ñ§Ò©ÎïÖÎÁÆ chemotherapy
»·¾³Ò©Àíѧ environmental pharmacology
»ù±¾Ò©Îï essential drugs
»ùÒò gene
¼¤»î¼Á activator
¼¤»î×÷Óà activation
¼¤ËØ hormone
¼¤ËØÔ­ prohormone
¼±ÐÔ¶¾ÐÔʵÑé acute toxicity test
¼ºÌÇ´¼Ï¸°û¶¾¼Á cytotoxic hexitols
¼ÁÁ¿ dosage; dose
¼ÁÁ¿»òŨ¶ÈµÄÒÀ´æÐÔ dose or concentration dependency
¼ÁÐÍ dosage form
¼ä½ÓÖ°© indirect carcinogenesis
¼äЪÃð¾ú·¨ discontinuous sterilization
¼îÖж¾ alkalosis;alkali-poisoning
½ºÌåÈÜÒºÐÍÒ©¼Á medical colloidal solution
½ÀÓÃÆ¬ chewable tablets
½Í½â glycolysis
Þ׿¹×÷Óà antagonism
½â¶¾×÷Óà detoxication
½éÖÊ mediator; transmitter; medium
¾«ÉñÒÀÀµÐÔ psychic dependence
¾çÒ© powerful drug
¾ø¶ÔÖÂËÀ¼ÁÁ¿ absolute lethal dose; LD100
¿¹¶¾ËØ antitoxin
¿¹¾úÆ× antibacterial spectrum
¿¹Ìå antibody
¿¹ÑªÇå antiserum
¿¹Ò©ÐÔ resistance to drugs
¿¹Ô­ antigen
¿Ëµ±Á¿ gram-equivalent weight
¿Ëµ±Á¿Êý gram-equivalent number
¿Ë·Ö×Ó gram-molecule; gram-mol
¿Ë·Ö×Ó·ÖÊý molar fraction
¿Ë·Ö×ÓÁ¿ gram molecular weight
¿Ë·Ö×ÓŨ¶È molar comcentratin; molal comcentration
¿ËÔ­×Ó gram-atom
¿ØÊÍÖÆ¼Á controlled release preparation
¿ÚÇ»ÄÚ¸øÒ© oral administration
¿ìËÙÄÍÊÜ tachyphylaxis
À©É¢ diffusion
À©É¢ÏµÊý coefficient of diffusion
ÀÛ»ýÄòÅÅйÇúÏß cumulative urinary excretion curves
ÀÛ¼ÓЧӦ additive effect
Àà¶¾ËØ anatoxin;toxoid
Àà¹Ì´¼Í£Ò©×ÛºÏÕ÷ steroid withdrawal syndrome
À䲨 cold-storage
Àä¶³ freezing;refrigeration
Á¿×ÓÒ©Àíѧ quantum pharmacology
ÁÙ´²Ò©Àíѧ clinical pharmacology
ÁÙ´²Ò©Ñ§ chlinical pharmacy
±»¯Îï halogenide
ÂñÖ²¼Á implants
ÂýͨµÀ slow pathway
ÂýÐÔ¶¾ÐÔʵÑé chronic toxicity test; long term toxicity test
ø enzyme
øԭ proenzyme
ÃâÒßÒÖÖÆ¼Á immunosuppressant;immuno inhibitor
ÃâÒßÔ­ÐÔ immunogenicity
ÃâÒßÔöÇ¿¼Á immunoenhancement
Ãô¸ÐÐÔ sensitivity
Ħ¶û mole
Ħ¶û·ÖÊýŨ¶È mol fraction concentration
Ħ¶û·Ö×ÓÌå»ý molar volume;mole volume
Ħ¶ûŨ¶È molarity
Ĭ¿ËË÷Òý the Merck index
ÄÍÊÜÐÔ tolerance
ÄÍÒ©ÐÔ drug tolerance
ÄÚ¶¾ËØ endotoxin
ÄÚ¶¾ËØö×ÊÔ¼Á²â¶¨·¨ Limulus Amebocyte Lysate assay for endotoxin
ÄÚÏûÐýÌå mesomer
Ũ¶È concentration
Ƥ·ô¡¢Õ³Ä¤±íÃæ¸øÒ© skin and mucocutaneous administration
Ƭ¼ÁÓ²¶È tablet hardness
ÆøÄý½º aerogel
ÆøÈܽº aerosol
ÆøÌå·ÖÎö gas analysis
ÆøÎí¼Á aerosol
ǰÌåÒ©Îï prodrug
ÇÊÄÚ×¢Éä intrathecal injection
ȫøÓ븨»ù holonzyme and prosthetic group
È˹¤ºÏ³É¿¹Ô­ artificial antigen
È˹¤ÃâÒß artificial immunization
ÈËÖÖÒ©Àíѧ ethnopharmacology
ÈÕÄÚÍßÃüÃû·¨ Geneva nomenclature
ÈܼÁ solvent; dissolvent
Èܽâ dissolution; dissolving
Èܾúø lysozyme
ÈÜѪ hemolysis
ÈÜÖÊ solute
ÈýôÈËáÑ­»· tricarboxylic acid cycle
ɱ¾ú»îÐÔ bactericidal activity
ɱ¾ú×÷Óà bactericidal effect
ÉíÌåÒÀÀµÐÔ physical dependence
Éñ¾­¶¾ËØ neurotoxin
ÉöÉÏÏÙËØÄÜÉñ¾­ adrenergic nerve
ÉöÉÏÏÙËØÄÜÊÜÌå adrenergic receptor
ÉøÍ¸Ñ¹ osmotic pressure
Éú³¤ÇúÏß growth curve
ÉúÎï°· biogenic amine
ÉúÎï°ëË¥ÆÚ biological half life
ÉúÎﻯѧ biochemistry
ÉúÎï¼î alkaloid
ÉúÎïÀûÓÃ¶È bioavailability
ÉúÎïͳ¼ÆÑ§ biometrics;biometry
ÉúÎïÒ©¼Áѧ biopharmacy
ÉúÎïÖÆÆ· biological product
ÉúÒ© crude drugs
ʱ³½Ò©Àíѧ chronopharmacology
ʱ¼ä¸ÐÊÜÐÔ chronosusceptability
ʱ¼äÖÎÁÆ chronotherapy
ʱЧ¹ØÏµ time-effect relationship
ʱֵ chronaxia;chronaxy
ʱÖÍ lag time
ÊÀ½çÎÀÉú×éÖ¯ World Health Organization; WHO
ÊɾúÌå bacteriophage
ÊÕÁ²Ò© astringent
ÊÖÐÔÒ©Îï chiral drug
Ê×¹ýЧӦ first-pass effect
ÊÜÌå receptor
ÊÜÌ弤¶¯¼Á receptor stimulant
ÊÜÌåÞ׿¹¼Á receptor antagonist
˫ä·¨ double-blind technique
Ë®½â£¨×÷Óã© hydrolysis
ÌÇÒìÉú×÷Óà gluconeogenesis
Ìå±íÃæ»ý body surface area
Ìå»ý±ÈŨ¶È volume by volume concentration
ÌåÒº body fluid
ÌåÒºÃâÒß humoral immunity
ÌìÈ»¿¹Ìå natural antibody
ÌìÈ»¿¹Ô­ natural antigen
ÌìÈ»ÃâÒß natural immunity
ÌìȻҩÎï crude drugs; natural drugs
µ÷¼Áѧ dispensing pharmacy
Í¬Î»ËØ isotope
Í»±ä mutation
ÍÌÊÉ×÷Óà phagocytosis
Íâ¶¾ËØ exotoxin
ÍâÏûÐýÌå raceme
ÍêÈ«¿¹Ô­ complete antigen
ÍõË® aqua regia; nitrohydrochloric acid
΢Á£Ìåø microsomal enzyme
΢Á¿ÔªËØ trace element
ÎÈ̬ѪҩŨ¶È steady state plasma concentration
ÎïÀíÒ©¼Áѧ physical pharmaceutics
ÎüÈë·¨ inhalation
ÎüÊÕËÙÂʳ£Êý absorption rate constant
ϸ°ûÃâÒß cellular immunity
ÏÙÜÕÁ×Ëá adenosine phosphate
ÏÞÖÆÐÔ¾çÒ© restrictive holagogue
Ïà¶Ô¸øÒ©¼ä¸ô relative dosage interval
Ïà¼Ó×÷Óà additive effect; addition
Ïò°Ð¸øÒ© targetable drug delivery
Ïû³ýËÙÂʳ£Êý elimination rate constant
Ч¼Û potency
Ч¼Ûµ¥Î» potency unit
Ч¼ÛÇ¿¶È potency
ЧӦ effect
ЧӦÆ÷ effector
ЧӦÎï effector
Э¶¨´¦·½ cipher prescription
Эͬ×÷Óà synergism
ÐË·ÜÐÔ excitability
Ðò¹áÉè¼Æ sequential design
Ðü¸¡Òº suspension
Ñ¡ÔñÐÔ selectivity
Ѫ¹ÜÄÚ¸øÒ© intravascular administration
Ѫ¹ÜÍâ¸øÒ© extravascular administration
Ѫ½¬ plasma
Ѫ½¬´úÓÃÒº plasma substitute
Ѫ½¬µ°°×½áºÏÂÊ plasma protein binding ratio
ѪÄÔÆÁÕÏ blood-cerebral barrier
ѪÇå serum
ѪÈÝÁ¿À©³ä¼Á blood volume expander
ѪҩŨ¶È blood concentration
ѪҺÄý¹Ì blood coagulation
ÑªÒºÖÆÆ· blood products
ÑǼ±ÐÔÖж¾ subacute intoxication;subacute poisoning
ÑÇÏõËáÑÎÖж¾ nitrite poisoning
ÑÛÓÃĤ¼Á ocular inserts
Ò©¡ªÊ±°ë¶ÔÊýÇúÏß semi-logarithmic curve of drug-time
Ò©¡ªÊ±ÇúÏß drug-time curve
Ò©·åŨ¶È peak concentration of drug
Ò©·åʱ¼ä peak time of drug
Ò©¼ÁµÈЧÐÔ pharmaceutical equivalence
Ò©¼Áѧ pharmaceutics
Ò©Àíѧ pharmacology
Ò©ÃôÊÔÑé drug sensitive test
Ò©Æ·¸ºÔðÆÚ allotted date of drug quality ensuring by manufacturer
Ò©Æ·¹ÜÀí·¨ drug administration law
Ò©Æ·ÅúºÅ drug batch number
ҩƷʹÓÃÆÚ limit date of using a drug after its production
Ò©Æ·ÓÐЧÆÚ expiry date; date of expiration
Ò©Æ·ÖÊÁ¿±ê×¼ drug standard
Ò©Îï´úл drug metabolism
Ò©Îï´úлø drug metablic enzyme
Ò©ÎïµÄÌåÄÚ¹ý³Ì intracorporal process of drugs
Ò©ÎﶯÁ¦Ñ§Ä£ÐÍ pharmacokinetics model
Ò©Îï·´Ó¦ drug reaction
Ò©Îï·Ö²¼ drug distribution
Ò©Îï·ÖÎö pharmaceutical analysis
Ò©Îﻯѧ pharmaceutical chemistry
Ò©ÎïÅÅй drug excretion
Ò©ÎïÎüÊÕ drug absorption
Ò©ÎïÏ໥×÷Óà drug interaction
Ò©ÎïÏû³ý drug elimination
Ò©ÎïÐî»ý drug accumulation
Ò©Îïѧ pharmacology; materia medica
Ò©ÎïÒÅ´«Ñ§ pharmacogenetics
ҩЧ¶¯Á¦Ñ§ pharmacodynamics
Ò©Ô´ÐÔ¼²²¡ drug-induced diseases
ÒÒõ£µ¨¼îÒÒõ£µ¨¼î acetylcholine
ÒÒõ£µ¨¼îõ¥Ã¸ acetylcholinesterase
ÒÖ¾ú»îÐÔ bacteriostatic activity
ÒÖ¾ú×÷ÓÃ bactriostasis
Ò칹ø isomerase
ÓªÑøËØ nutrient
Ó²¸à¼Á plaster
ÓÐЧ°ëË¥ÆÚ effective halt
ÓÐЧÂÊ effective rate
ÓÐЧŨ¶È effective concentration
ÓÒÐýÌÇ dextrose
ÓÒÐýÌå dextrorotatory form
ãмÁÁ¿ threshold dose
ÔØÌå carrier
Ôíß° saponins
Ö¬ÖÊÌå liposome
Ö±³¦¸øÒ© rectal administration
Ö±ÏßÏà¹Ø linear correlation
Ö½ÐÍÆ¬¼Á oral medicaed soluble paper
Ö°©ÊµÑé carcinogenic test
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÒÀË®·ðÀ¼

³¬¼¶°æÖ÷

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


¡ï¡ï¡ï ÈýÐǼ¶,Ö§³Ö¹ÄÀø

²»´í
лл·ÖÏí£¡
10Â¥2009-03-04 20:38:29
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 16 ¸ö»Ø´ð

Annette

¹ÜÀíÔ±

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


¶¥Ò»Ï£¬ËäÈ»ÏÖÔÚ»¹Óò»µ½
2Â¥2008-05-14 15:31:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

eagleking

°æÖ÷

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


¡ï¡ï¡ï ÈýÐǼ¶,Ö§³Ö¹ÄÀø

¶ÔÎÒÃÇ¿´ÎÄÏ׺ÜÓÐÓÃ
3Â¥2008-10-23 23:59:34
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

liuqiuwei

¹ÜÀíÔ±

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


ºÜÓÐÓõģ¬Ö§³ÖÒ»ÏÂÁË¡£
4Â¥2008-10-25 10:49:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁϹ¤³Ì085601Êý¶þÓ¢Ò»335Çóµ÷¼Á +5 Ë«ÂíβƦÀϰå2 2026-03-31 5/250 2026-03-31 19:07 by Wang200018
[¿¼ÑÐ] 0856²ÄÁÏ»¯¹¤µ÷¼Á ×Ü·Ö330 +17 zhubinhao 2026-03-27 17/850 2026-03-31 18:56 by СÕÅ×öʵÑé
[¿¼ÑÐ] 08¹¤¿Æ£¬295£¬½ÓÊÜ¿çרҵµ÷¼Á +4 lmnlzy 2026-03-31 4/200 2026-03-31 15:25 by Î÷¾©Ñ§ÔºÕаì
[¿¼ÑÐ] 282Çóµ÷¼Á ²»Ìôרҵ ÇóÊÕÁô +4 Yam. 2026-03-30 5/250 2026-03-31 14:41 by ÍõÁÁ_´óÁ¬Ò½¿Æ´ó
[¿¼ÑÐ] 08¹¤¿ÆÇóµ÷¼Á286 +5 tgs_001 2026-03-28 5/250 2026-03-31 08:18 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] ±¾¿Æ211×Ü·Ö289£¬08¹¤Ñ§ÕæÐÄÇóµ÷¼Á +3 utopiaE 2026-03-30 3/150 2026-03-30 23:42 by ms629
[¿¼ÑÐ] ÉúÎïѧѧ˶£¬Ò»Ö¾Ô¸ºþÄÏ´óѧ£¬³õÊԳɼ¨338 +7 YYYYYNNNNN 2026-03-26 9/450 2026-03-30 20:29 by YYYYYNNNNN
[¿¼ÑÐ] 289Çóµ÷¼Á +16 ÐÂʱ´ú²ÄÁÏ 2026-03-27 16/800 2026-03-30 19:04 by Wang200018
[¿¼ÑÐ] »·¾³¿ÆÑ§Ó빤³Ì334·ÖÇóµ÷¼Á +6 ÍõÒ»Ò»ÒÀÒÀ 2026-03-30 8/400 2026-03-30 11:52 by yjolah
[¿¼ÑÐ] 332Çóµ÷¼Á +6 Lyy930824@ 2026-03-29 6/300 2026-03-30 10:53 by 1172367218
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©Àí¹¤´óѧ±¾¿Æ211²ÄÁϹ¤³Ì294Çóµ÷¼Á +8 mikasaµÄΧ½í 2026-03-28 8/400 2026-03-29 12:48 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 298Çóµ÷¼Á +3 ÖÖÊ¥´Í 2026-03-29 3/150 2026-03-29 12:06 by longlotian
[¿¼ÑÐ] ÊýÒ»Ó¢Ò»271ר˶£¨085401£©Çóµ÷¼Á£¬¿É¿ç +7 ǰÐбØÓйâ 2026-03-28 8/400 2026-03-28 23:22 by Сľ³ætim
[¿¼ÑÐ] 070300Çóµ÷¼Á306·Ö +4 26ÒªÉϰ¶ 2026-03-27 4/200 2026-03-28 13:06 by ÌÆãå¶ù
[¿¼ÑÐ] 085701»·¾³¹¤³Ì£¬267Çóµ÷¼Á +16 minht 2026-03-26 16/800 2026-03-28 12:16 by zllcz
[¿¼ÑÐ] 081200-314 +3 LILIQQ 2026-03-27 4/200 2026-03-28 09:41 by ±£»¤µØÇòÄãÎÒ×öÆ
[˶²©¼ÒÔ°] ±±¾©ÁÖÒµ´óѧ˶µ¼ÕÐÉú¹ã¸æ +6 kongweilin 2026-03-26 8/400 2026-03-27 10:18 by FF_16
[¿¼ÑÐ] 341Çóµ÷¼Á +7 ÇàÄûÃÊ1 2026-03-26 7/350 2026-03-27 00:19 by wxiongid
[¿¼ÑÐ] ÍøÂç¿Õ¼ä°²È«0839Õе÷¼Á +4 w320357296 2026-03-25 6/300 2026-03-25 17:59 by 255671
[¿¼ÑÐ] Çóµ÷¼Á +3 ÀîÀî²»·þÊä 2026-03-25 3/150 2026-03-25 13:03 by cmz0325
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û